Search alternatives:
mean decrease » a decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
ng decrease » _ decrease (Expand Search), a decrease (Expand Search), we decrease (Expand Search)
100 ng » 100 mg (Expand Search), 100 nm (Expand Search), 100 ns (Expand Search)
mean decrease » a decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
ng decrease » _ decrease (Expand Search), a decrease (Expand Search), we decrease (Expand Search)
100 ng » 100 mg (Expand Search), 100 nm (Expand Search), 100 ns (Expand Search)
-
241
-
242
Bioinformatics analysis of the gene pathways that were enriched in the N.g MDP–treated osteocytes and verification <i>in vitro</i>.
Published 2022“…Green arrow, BMSCs; blue arrow, osteoblast; red arrow, osteocyte; Control, the sample was treated with culture medium in vitro or saline only in vivo; MDP, the sample was treated with 1 μg/ml N.g MDP for 36 h in vitro or 2 μg N.g MDP dissolved in 100 μl of saline solution for 10 days in vivo.…”
-
243
-
244
-
245
-
246
-
247
-
248
-
249
-
250
-
251
-
252
-
253
Demographic, clinical, and densitometric characteristics of study participants.
Published 2023Subjects: -
254
-
255
-
256
-
257
Annual treatment frequencies in all eyes.
Published 2025“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
-
258
Annual number of outpatient visits in recurrence and non-recurrence groups.
Published 2025“…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
-
259
Annual number of outpatient visits in all eyes.
Published 2025“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
-
260
Annual treatment frequencies in recurrence and non-recurrence groups.
Published 2025“…(<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g007" target="_blank">Fig 7</a>). Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”